10 Best Diabetes Stocks To Buy According to Billionaires

3. Thermo Fisher Scientific Inc. (NYSE:TMO)

Number of Billionaires: 16

Dollar Value of Billionaire Holdings: $3,809,975,968

Thermo Fisher Scientific Inc. (NYSE:TMO) offers a wide range of products and services, including analytical instruments, diagnostics, and life sciences solutions. It stands out for its comprehensive portfolio and customer-centric innovations. In diabetes care, the company provides products like the MAS Diabetes Control line for precise hemoglobin A1c testing. Its PPD clinical research business plays a key role in advancing diabetes treatments.

Thermo Fisher Scientific Inc. (NYSE:TMO) reported strong Q4 2024 results, with revenue of $11.4 billion, a 5% year-over-year increase which was driven by robust performance in the Analytical Instruments segment and overall market strength. This growth was supported by a 7% increase in adjusted operating income and a 50-basis point expansion in operating margin to 23.9%, reflecting improved cost management and profitability. Adjusted EPS grew by 8%, reaching $6.10 for the quarter.

For the full year, Thermo Fisher Scientific Inc. (NYSE:TMO) generated $42.9 billion in revenue and $9.71 billion in adjusted operating income. The company also delivered $7.3 billion in free cash flow and returned $4.6 billion to shareholders through stock buybacks and dividends, signaling confidence in its financial health. Looking ahead to 2025, the corporation expects revenue to reach $43.5 billion to $44 billion, with a 3% to 4% organic growth, and adjusted EPS of $23.10 to $23.50, representing a 6% to 8% growth. The company is also recognized for its role in healthcare innovation, and with its expanding presence in diabetes research, it ranks among the best diabetes stocks attracting investor interest.